Im aware of the herceptin breast cancer data. Basically, the survival of her2 neu positive patients is now about the same as that of negative patients. There is still a significant relapse rate even with herceptin. Furthermore, herceptin does not cross the blood brain barrier so a good number of positive patients develop and die from brain mets in spite of being treated with herceptin. So I think a combo trial would be interesting. But first a phase 2 trial would be in order.
Ovarian ca is much less common and 75% of those patients are her2neu negative. Im wondering whether the presence of the her2neu receptor on the surface of some ovarian ca patients has any therapeutic significance in humans.
Hopefully dendreon will convene an advisory meeting of experts to get some needed guidance before embarking on ovarian cancer or any other pipeline project. Ive participated in several of those in the past with other drugs/therapies and they are quite enlightening and helpful in providing direction to a company.
News 
Market Data 
Discover 
AI
